Crossmark

SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity

Published Online: 2019-09-11

Authors

Yin, Fan

Feng, Fan

Wang, Lei

Wang, Xiaoning

Li, Zongwei

Cao, Yu http://orcid.org/0000-0003-3708-575X
Funding

Funding for this research was provided by:

PLA general hospital internal grant
License Information

Text and Data Mining valid from 2019-09-11

Version of Record valid from 2019-09-11
More Information

Article History

Received: 1 July 2019

Revised: 20 August 2019

Accepted: 26 August 2019

First Online: 11 September 2019

Conflict of interest

: The authors declare that they have no conflict of interest.

Document is current